Associate Professor of Surgery Division of Adult Cardiothoracic Surgery
2340 Sutter Street N-221, Box 1724 University of California, San Francisco San Francisco, CA 94143-1724 (415) 476-6906 Phone email@example.com
1982-87, Jinzhou Medical College, Jinzhou, P.R.C., M.D. , Medicine
1988-94, Medical College of Ohio, Toledo, Ohio, Ph.D., Pathology
1997-2002, UCSF, Staff Research Associate, Dept. of Surgery, UCSF Comprehensive Cancer Center
Thoracic Oncology Program
Thoracic Oncology Laboratory
UCSF Helen Diller Family Comprehensive Cancer Center
Akt Signaling Pathway
Human cancer genetics and epigenetics
Lung cancer and mesothelioma
Molecular analysis on matched normal/tumor tissues
Small molecules, antibodies and recombinant proteins
Wnt Signaling Pathway
Dr. Liang You received his M.D. in 1987 from the Jinzhou Medical College in China and his Ph.D. in pathology from the Medical College of Ohio in 1994. He began work at UCSF in the thoracic oncology laboratory after work at the National Cancer Institute. At UCSF, Dr. You has made a significant impact on lung cancer and mesothelioma research. Most notably, he has been been instrumental in helping Dr. David Jablons mold a fledgling research effort into a thriving molecular genomics laboratory, an integral part of the Comprehensive Cancer Center and nationally recognized.
In November 2007, Dr. You was presented with the David Jablons "Asclepios" Award by the Bonnie J. Addario Lung Cancer Foundation for his pioneering research.
Dr. You has been a creative and dynamic force in the lab and his work has led to numerous discoveries. He helped demonstrate the relationship of p14ARF tumor suppressor deletions to the p53 pathway in mesothelioma and the effects of oncolytic viruses upon these tumors. He also discovered several novel mechanisms for the activation of upstream WNT pathways.
Dr. You has helped identify several novel biomarkers and therapeutic targets in lung cancer and mesothelioma. He and his colleagues demonstrated overexpression of Dishevelled-3 and silencing of SFRP-2, SOCS-3 and WIF-1 through promoter methylation. Dr. You and chemist Dr. Naoaki Fujii developed a small molecule Wnt pathway inhibitor, FJ9, that disrupts the interaction between the Frizzled receptor and Dishevelled, a Wnt signal transducer.
Dr. You is currently investigating the use of recombinant human WIF-1 protein as a cancer therapy and seeking out new therapeutic targets and novel interventions.
Most recent publications from a total of 62
You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM, You L. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget. 2015 Feb 28; 6(6):4357-68. View in PubMed
Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang L, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. CK2¿, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res. 2014 Nov 25; 33(1):93. View in PubMed
Yang YL, Jablons D, You L. An alternative way to initiate Notch1 signaling in non-small cell lung cancer. Transl Lung Cancer Res. 2014 Aug; 3(4):238-41. View in PubMed
Yang YL, Hung MS, Wang Y, Ni J, Mao JH, Hsieh D, Au A, Kumar A, Quigley D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L. Lung tumourigenesis in a conditional Cul4A transgenic mouse model. J Pathol. 2014 Jun; 233(2):113-23. View in PubMed
Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014 Jan 15; 74(2):520-31. View in PubMed
Hung MS, Xu Z, Chen Y, Smith E, Mao JH, Hsieh D, Lin YC, Yang CT, Jablons DM, You L. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model. Int J Oncol. 2013 Nov; 43(5):1517-22. View in PubMed
Liu S, Hsieh D, Yang YL, Xu Z, Peto C, Jablons DM, You L. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2. BMC Pharmacol Toxicol. 2013; 14:36. View in PubMed
Bravo DT, Yang YL, Kuchenbecker K, Hung MS, Xu Z, Jablons DM, You L. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer. 2013; 13:316. View in PubMed
Zhang S, Long H, Yang YL, Wang Y, Hsieh D, Li W, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. Inhibition of CK2a down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med. 2013 Jul; 17(7):854-62. View in PubMed
Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012; 7(6):e38996. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.